NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Biocon EGM Approves Fundraise, Preferential Issue, and Mylan Related Party Transactions
Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.
முக்கிய அம்சங்கள்
Approval sought for increasing the Authorised Share Capital and amending the Memorandum of Association.Proposed raising of funds in one or more tranches through issuance of equity shares or other securities.Issuance of Equity Shares on a preferential basis for consideration other than cash.Approval for material related party transactions with Mylan Inc., a related party of Biocon Biologics.Increased limits for making investments, extending loans, and providing guarantees under Section 186.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific terms of the fundraise and the identity of the preferential allottees to assess potential dilution. The non-cash preferential issue and Mylan transaction suggest a strategic settlement or asset acquisition that could impact long-term valuation.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.
முக்கிய அம்சங்கள்
Acquisition of full global rights for manufacturing and commercialization of biosimilar Adalimumab (Hulio).Transition from a commercialization-only model to an end-to-end integrated model for the product.FKB to offset certain development costs while Biocon pays technology license fees and royalties.Strategic focus on the immunology portfolio, which currently includes three major biosimilars.Commercial production at Biocon facilities to commence following technology transfer and regulatory approvals.
👀 கவனிக்க வேண்டியவை
This vertical integration is a margin-accretive move that provides Biocon with greater control over its supply chain and product development. Investors should monitor the timeline for technology transfer and regulatory approvals for the in-house manufacturing of Hulio.
Biocon Limited has successfully issued Commercial Papers (CP) worth Rs 1,800 Crores on a private placement basis. The short-term debt instrument carries a competitive interest rate of 6.85% and has a tenure of 88 days, maturing on March 20, 2026. The issue has been subscribed by major institutional investors including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life. The high credit rating of IND A1+ underscores the company's strong short-term credit profile.
முக்கிய அம்சங்கள்
Total issue size of Rs 1,800 Crores via private placement to mutual fundsShort-term tenure of 88 days with maturity scheduled for March 20, 2026Competitive coupon rate of 6.85% per annumAssigned a top-tier credit rating of IND A1+ by India RatingsProposed to be listed on the National Stock Exchange (NSE)
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine short-term liquidity management exercise. The low interest rate and high credit rating indicate strong market confidence in Biocon's financial stability.
Biocon Receives US FDA EIR with VAI Status for New Jersey Generics Facility
Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.
முக்கிய அம்சங்கள்
US FDA issued an Establishment Inspection Report (EIR) for the Cranbury, New Jersey facility.The inspection was conducted over a 5-day period from October 6 to October 10, 2025.The facility received a 'Voluntary Action Indicated' (VAI) classification, avoiding more severe regulatory sanctions.The EIR marks the formal closure of the inspection cycle for this specific U.S.-based manufacturing site.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development that reduces compliance risk for Biocon's U.S. operations. This clearance supports the company's ability to maintain supply and seek new product approvals from this facility.
Biocon Retains [ICRA]AA+ Rating; To Acquire BBL Minority Stakes for $1.17 Billion
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash payment, making BBL a wholly-owned subsidiary. To fund the cash component and repay existing structured debt, Biocon plans a QIP of up to Rs. 4,500 crore. This restructuring aims to simplify the group's corporate structure and consolidate BBL, which contributed 58% of consolidated revenues in FY2025.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated instruments.Acquisition of minority stakes in BBL valued at $1.17 billion from Mylan, Serum Institute, and others.Funding includes a share swap of 171.3 million shares and $400 million cash funded via CP and a Rs. 4,500 crore QIP.BBL is the largest revenue contributor, accounting for 58% of Biocon's consolidated revenue in FY2025.Structured debt from the Viatris acquisition is scheduled to be repaid by January 31, 2026, using QIP proceeds.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful execution and pricing of the Rs. 4,500 crore QIP, as it is critical for the company's deleveraging and the BBL consolidation. The move is a long-term positive as it simplifies the corporate structure and eliminates the holding company discount.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
ICRA Reaffirms Biocon's AA+ Rating; Highlights $1.17B Biocon Biologics Consolidation
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated limits.Biocon to acquire minority stakes in Biocon Biologics for $1.17 billion, making it a 100% subsidiary.Funding includes a Rs. 6,950 crore share swap and a $400 million cash payment.Company plans a QIP of up to Rs. 4,500 crore to repay bridge financing and structured debt by Jan 2026.Biocon Biologics is the largest revenue contributor, accounting for 58% of consolidated FY25 revenue.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful completion of the Rs. 4,500 crore QIP as it is crucial for deleveraging the balance sheet. The consolidation of the biologics business is a strategic positive that eliminates holding company discounts and simplifies the corporate structure.
Biocon launches Liraglutide (gVictoza®) in Netherlands
Biocon Limited has launched its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. Liraglutide was approved for medical use in the European Union in 2009.
முக்கிய அம்சங்கள்
Biocon launched Liraglutide in the Netherlands on December 15, 2025.Liraglutide will be marketed as Diavorin® for diabetes.Liraglutide will be marketed as Vobexoryn® for chronic weight management.Liraglutide was approved for medical use in the European Union in 2009.
👀 கவனிக்க வேண்டியவை
This launch in the Netherlands is a positive step for Biocon, indicating expansion in the European market; investors should monitor the sales performance of Diavorin® and Vobexoryn® in the coming quarters.
Biocon Biologics to Commercialize Biosimilar Aflibercept Worldwide
Biocon Biologics has signed a settlement and license agreement to commercialize biosimilar Aflibercept (YESAFILI) worldwide. This agreement with Regeneron and Bayer covers Europe and the rest of the world, following a previous settlement for the US and Canada. YESAFILI is a VEGF inhibitor used for ophthalmology conditions. The company plans to launch YESAFILI in the UK in January 2026 and in other settled countries by March 2026 or earlier.
முக்கிய அம்சங்கள்
Biocon Biologics will commercialize biosimilar Aflibercept (40mg/ml) worldwide.YESAFILI launch in the United Kingdom is planned for January 2026.YESAFILI launch in other settled countries is planned for March 2026 or earlier.Biocon Biologics has commercialized 10 biosimilars across 120+ countries.
👀 கவனிக்க வேண்டியவை
This agreement expands Biocon Biologics' global presence in the ophthalmology therapeutic area. Investors should monitor the launch and market uptake of YESAFILI in 2026.
S&P Global Places Biocon Biologics on Positive CreditWatch; Debt to Drop to ₹120 Billion
S&P Global Ratings has placed Biocon Biologics on 'CreditWatch Positive' following a major restructuring plan to make it a 100% subsidiary of Biocon Limited. The company aims to reduce its adjusted debt significantly from INR 248 billion in March 2025 to approximately INR 120 billion by March 2026. This reduction will be driven by swapping $1 billion in debt-like CCPS held by Viatris for equity and cash, alongside a planned INR 45 billion fresh equity issuance. The move simplifies the capital structure and eliminates minority put options that were previously viewed as debt-like obligations.
முக்கிய அம்சங்கள்
S&P Global placed 'BB' rating on CreditWatch Positive, signaling a potential upgrade within 60-90 days.Adjusted debt is projected to fall by over 50% to INR 120 billion by the end of FY26.Biocon to acquire the remaining 25% stake in Biocon Biologics from minority investors including Viatris and Serum Institute.Viatris' $1 billion CCPS will be settled through $415 million in Biocon equity and $400 million in cash.The cash component for the transaction is intended to be funded via a fresh INR 45 billion equity raise.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major positive for the balance sheet as it significantly reduces leverage and simplifies the corporate structure. Key monitorables include the successful execution of the INR 45 billion equity fundraise and the final resolution of the CreditWatch by S&P.
India Ratings has assigned 'IND AA+/Stable/IND A1+' to Biocon's bank loan facilities of INR 5,500 million and 'IND A1+' to proposed commercial paper of INR 8,000 million. The agency has also affirmed 'IND AA+/Stable/ IND A1+' for existing bank loan facilities of INR 4,500 million and 'IND A1+' for proposed commercial paper of INR 12,000 million. The rating on non-convertible debentures of INR 10,700 million has been withdrawn as the instrument has been paid in full. These ratings reflect India Ratings' assessment of Biocon's creditworthiness.
முக்கிய அம்சங்கள்
INR 5,500 million bank loan facilities assigned IND AA+/Stable/IND A1+ ratingINR 8,000 million proposed commercial paper assigned IND A1+ ratingINR 4,500 million bank loan facilities affirmed at IND AA+/Stable/ IND A1+INR 12,000 million proposed commercial paper affirmed at IND A1+INR 10,700 million non convertible debenture rating withdrawn
👀 கவனிக்க வேண்டியவை
Investors should monitor Biocon's debt levels and credit ratings for any changes. The affirmed and assigned ratings indicate a stable outlook for the company's debt obligations.
Biocon to Consolidate 100% Stake in Biocon Biologics via $1.17 Billion Deal
Biocon Limited has announced a major consolidation plan to acquire the remaining 23.3% minority stake in Biocon Biologics, making it a 100% subsidiary. The transaction involves a $773 million share swap (171.3 million shares at ₹405.78 each) and a $400 million cash payment to Viatris. This move is designed to simplify the corporate structure, eliminate the holding company discount, and improve financial metrics, with a proforma Net Debt/EBITDA ratio of 2.5x. The company expects the transaction to be completed by Q4 FY2026, following a shareholder vote on December 31, 2025.
முக்கிய அம்சங்கள்
Acquisition of 23.3% minority stake from Viatris, Serum Institute, Tata Capital, and True North.Total consideration includes $773M in equity shares and $400M in cash funded via QIP or bridge loans.Consolidation expected to generate annual interest savings of ₹300 crore.Proforma Net Debt/EBITDA reduced to 2.5x from 4.3x in FY23 through deleveraging and EBITDA growth.Targeting transaction completion by Q4 FY2026 with a long-stop date of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this consolidation as it simplifies the group structure and removes the holding company discount. Monitor the upcoming EGM on December 31 and the successful execution of the $400M cash funding through a QIP or rights issue.
Biocon to Issue 17.13 Cr Shares at ₹405.78 and Raise Investment Limits to ₹20,000 Cr
Biocon has convened an Extra-Ordinary General Meeting (EGM) on December 31, 2025, to seek approval for significant capital restructuring. The company proposes to issue up to 17,12,79,553 equity shares on a preferential basis at ₹405.78 per share for consideration other than cash. Additionally, it seeks to increase its authorized share capital to ₹900 crore and significantly expand its investment and loan limits under Section 186 to ₹20,000 crore. These moves suggest a major upcoming acquisition or strategic asset integration.
முக்கிய அம்சங்கள்
Preferential issuance of up to 17.13 crore equity shares at a fixed price of ₹405.78 per shareProposed increase in Authorized Share Capital from ₹700 crore to ₹900 croreExpansion of Section 186 limits for loans, guarantees, and investments to ₹20,000 croreThe share issuance is for 'consideration other than cash', indicating a potential swap or acquisitionEGM scheduled for December 31, 2025, with a voting cut-off date of December 24, 2025
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the specific details of the asset or entity being acquired in exchange for the 17.13 crore shares, as this represents significant equity dilution. The pricing of ₹405.78 serves as a key valuation benchmark for the stock in the near term.
Biocon to fully integrate Biocon Biologics via ₹6,950 Cr share swap and ₹4,500 Cr fundraise
Biocon Limited has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from Mylan, Serum Institute, Tata Capital, and Activ Pine to simplify its corporate structure. The transaction involves a preferential issue of 17.12 crore shares valued at approximately ₹6,950 crore as a share swap and a separate fundraise of up to ₹4,500 crore for cash consideration. Additionally, the company will issue Commercial Papers worth ₹1,800 crore for interim financing needs. This integration aims to create a larger balance sheet and a unified capital allocation strategy to maximize stakeholder value.
முக்கிய அம்சங்கள்
Acquisition of 40,55,86,862 shares of Biocon Biologics Limited to achieve full integration and operational synergies.Issuance of 17,12,79,553 equity shares on a preferential basis for a total value of up to ₹6,950 crore.Approved a fundraise of up to ₹4,500 crore via QIP or Rights Issue primarily to fund cash payments to Mylan Inc.Issuance of Commercial Papers up to ₹1,800 crore to manage interim cash requirements for the Mylan transaction.Increase in authorized share capital from ₹700 crore to ₹900 crore to facilitate the new share issuances.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant long-term strategic consolidation that simplifies the group structure, though they should monitor the potential equity dilution from the preferential issue and QIP.
Biocon to raise ₹4,500 Cr, acquires Biocon Biologics shares
Biocon Limited's board approved raising up to ₹4,500 Crores through various means to fund the cash consideration payable to Mylan. The company will also acquire equity shares of Biocon Biologics Limited (BBL) from multiple shareholders, including Mylan, Serum Institute, Tata Capital, and Activ Pine. As part of this acquisition, Biocon will issue 17,12,79,553 equity shares on a preferential basis, amounting to ₹6,950 Crores, for consideration other than cash. The board also approved an increase in authorized share capital from ₹700 Crores to ₹900 Crores.
முக்கிய அம்சங்கள்
Raising funds up to ₹4,500 Crores.Issuance of 17,12,79,553 equity shares on a preferential basis.Increase in authorized share capital from ₹700 Crores to ₹900 Crores.Acquisition of 40,55,86,862 shares of Biocon Biologics Limited (BBL).Issuance of Commercial Papers for an amount up to ₹1,800 Crores
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the progress of the fund-raising and acquisition of Biocon Biologics shares, as these actions could significantly impact the company's financial structure and future growth prospects. Attend the Extra-Ordinary General Meeting on December 31, 2025 to vote on these proposals.
Biocon to consolidate Biocon Biologics; Analyst call on Dec 8, 2025
Biocon Limited will hold an analyst call on December 8, 2025, to discuss Biocon Biologics Limited’s integration with Biocon Limited. The acquisition of minority shareholder stake of 23.3% in Biocon Biologics will be funded through issuance of 171.3 MM equity shares in Biocon Limited and cash consideration of $400MM. The share swap ratio is 61.70 shares of Biocon for every 100 shares of BBL for BBL Shareholders. The transaction is expected to be completed by Q4 FY2026.
முக்கிய அம்சங்கள்
Acquisition of minority stake in Biocon Biologics to be funded through issuance of 171.3 MM equity sharesCash consideration of $400MM to be paid for acquisition of minority stakeShare swap ratio of 61.70 for BBL shareholdersBL share price considered for share swap at ₹ 405.78 per shareBiocon Ltd has a 52.4% stake in Syngene
👀 கவனிக்க வேண்டியவை
Investors should review the presentation and listen to the analyst call on December 8, 2025, to understand the strategic rationale and financial implications of the consolidation. Monitor regulatory approvals and shareholder consent for the transaction.
Biocon to Integrate Biocon Biologics, Valuing BBL at USD 5.5 Billion
Biocon Limited will fully integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary. Biocon will acquire the remaining stake in BBL from Serum, Tata Capital, and Activ Pine through a share swap of 70.28 Biocon shares for every 100 BBL shares, valuing BBL at USD 5.5 billion. Additionally, Biocon will acquire Viatris' stake for USD 815 million, including USD 400 million in cash and USD 415 million in shares. Biocon plans to raise up to ₹4500 crore (USD 500 million) through QIP to fund the cash component.
முக்கிய அம்சங்கள்
Biocon to acquire Biocon Biologics Limited (BBL) valuing BBL at USD 5.5 billion.Share swap ratio of 70.28 Biocon shares for every 100 Biocon Biologics shares.Acquisition of Mylan Inc. stake for USD 815 million, including USD 400 million cash.Plans to raise up to ₹4500 crore (USD 500 million) through Qualified Institutional Placement (QIP).
👀 கவனிக்க வேண்டியவை
Investors should note the share swap ratios and the potential dilution from the QIP. Monitor the progress of the integration, expected to be completed by March 31, 2026, and its impact on Biocon's long-term growth.
Biocon Pharma gets tentative US FDA nod for Carbidopa and Levodopa capsules
Biocon Limited's wholly-owned subsidiary, Biocon Pharma Limited, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for its ANDA for Carbidopa and Levodopa Extended-Release Capsules. The capsules are in strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. These capsules are used for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. This approval allows Biocon to potentially enter the market upon patent expiry.
முக்கிய அம்சங்கள்
Biocon Pharma received tentative US FDA approval for Carbidopa and Levodopa Extended-Release CapsulesCapsule strengths approved: 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mgThe capsules treat Parkinson's disease and related conditions
👀 கவனிக்க வேண்டியவை
This tentative approval is a positive sign for Biocon's expansion in the US market. Investors should monitor the final approval and launch plans for these capsules.
Biocon Biologics Secures Europe Entry for Denosumab Biosimilars Starting Dec 2, 2025
Biocon Biologics has settled with Amgen Inc., clearing the path to commercialize its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and the rest of the world starting December 2, 2025. This follows the European Commission's approval in July 2025 and a previous settlement for the U.S. market. The products target significant markets, including 32 million osteoporosis patients in Europe and oncology-related bone health, strengthening Biocon's global biosimilar portfolio of 10 commercialized assets.
முக்கிய அம்சங்கள்
Settlement with Amgen allows market entry for Denosumab biosimilars in Europe from December 2, 2025.Commercialization includes Vevzuo® for oncology and Evfraxy® for osteoporosis and bone loss.Targets a European market of 32 million individuals aged 50+ with osteoporosis and 2.74 million annual cancer cases.Follows prior U.S. market entry settlements, broadening Biocon's reach in the oncology and bone health therapeutic areas.Biocon Biologics currently serves over 6 million patients across 120+ countries with 10 commercialized biosimilars.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue ramp-up from these launches in late 2025, as they represent a significant expansion into the high-value European biosimilars market. The resolution of legal hurdles with Amgen reduces uncertainty regarding Biocon's global commercialization timeline.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
